Business brief
UK Corporates Face Private Buyout and Patent Hurdles
KKR's £5.75bn takeover of DCC Energy underscores London's valuation gap, while AstraZeneca's cancer portfolio shields it from patent expiries.
Business
KKR's £5.75bn buyout of DCC Energy strips another cash-rich giant from the FTSE 100 — proving that London's depressed valuations make its top firms easy prey for private capital.
BackgroundDCC Energy distributes liquid fuels and solar systems across Europe, acting as a critical middleman in the continental transition to cleaner energy. The company recently spun off its non-core technology divisions to focus solely on this energy infrastructure, making it a highly attractive target for infrastructure-focused funds.
- The recommended cash offer of up to 6,797p per share represents a 24% premium to DCC's undisturbed price, likely clearing the way for swift shareholder approval.
- KKR plans to deploy capital from its global infrastructure funds into DCC’s European network, accelerating the firm's transition into low-carbon services like heat pumps and solar installs.
- The acquisition removes another major cash-generative player from London’s premier index, reinforcing fears that UK public markets remain deeply undervalued compared to private equity alternatives.
Business
AstraZeneca’s double-digit profit growth proves its high-margin cancer treatments are successfully insulating the FTSE 100 bellwether from patent expirations — protecting its ambitious 2030 expansion plan.
BackgroundAstraZeneca is the UK's most valuable pharmaceutical group, relying heavily on high-margin cancer treatments to fund its massive research budget. The company recently faced the patent expiry of its blockbuster heart drug Farxiga, raising pressure on its newer pipeline to sustain growth.
- Core earnings per share rose 11% to $5.21, beating analyst estimates and reassuring investors that the group's underlying profitability remains intact despite rising operational costs.
- Oncology sales surged 15% to $14.1bn, cementing cancer care as the company’s primary valuation engine and offsetting weaker performance in its respiratory division.
- Management reaffirmed its target of $80bn in annual revenue by 2030, a goal that requires launching 20 new blockbusters over the next 4 years.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.